# Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults

> **NCT04866069** · PHASE1 · TERMINATED · sponsor: **Osman ERGANIS, PhD, Prof** · enrollment: 50 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04866069
- **Lead sponsor:** Osman ERGANIS, PhD, Prof
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-25
- **Primary completion:** 2021-09-05
- **Final completion:** 2021-09-05
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Although cellular responses to virus were satisfactory, neutralizing titres against virus were lower then expected levels
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866069, "Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04866069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*